Yiying Wang

Yiying Wang represents companies, investment banks and private equity funds in IPOs in the US and Hong Kong capital markets, cross-border M&A transactions, and various other corporate transactions.

Prior to joining Cooley, Yiying practiced in the Shanghai offices of other leading US law firms and PRC law firm.

Yiying is a native Mandarin speaker and is fluent in English. 

Representative Matters:

Capital Markets

• Joint sponsors and underwriters Morgan Stanley, Jefferies, CITIC Securities, CICC and CMB International Securities on HK$1.64 billion IPO and listing of Duality Biotherapeutics, a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases
• Joint sponsors and underwriters CICC and CMB International Securities on HK$$1.005 billion IPO and listing of Zenergy, a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products
• Joint sponsors and underwriters CICC and SPDB International on HK$583 million Hong Kong IPO of BrainAurora Medical Technology, a seasoned player in China's cognitive impairment digital therapeutics (DTx) market
• Joint sponsors and underwriters Morgan Stanley and CICC on HK$335 million IPO and listing of Taimei Technology, a healthtech company that delivers advanced digital solutions for the pharmaceutical and medical device industries
• Jiuyuan Gene Engineering, a modern biopharmaceutical company, specialized in R&D, manufacture and sales of gene engineering, on its HK$563.9 million Hong Kong IPO
• The sole sponsor CICC and other underwriters on HK$791 million (US$101 million) IPO and listing of Laekna, a leading biotechnology company, on HKEX
• ImmuneOnco, a clinical-stage biotech company, on its HK$319 million Hong Kong IPO, and its HK$234 million H share placement
• Akeso Biopharma’s HK$1.2 billion follow-on offerings
• Joint sponsors and underwriters Citi and Huatai International on Cryofocus Medtech's HK$210 million IPO and listing on HKEX
• Asymchem in its US$979 million IPO and listing on the HKEX. This is the largest healthcare HK IPO in 2021.
• Keymed Biosciences in its US$400 million IPO and listing on the HKEX
• Betta Pharmaceuticals Co., Ltd. in its proposed IPO and listing on the HKEX
• Jacobio Pharmaceuticals in its US$174 million IPO and listing on the HKEX
• RemeGen in its US$515 million IPO and listing on the HKEX
• Akeso Biopharma in its US$383 million IPO and listing on the HKEX
• Innovent Biologics in its US$421 million IPO and listing on the HKEX
• Goldman Sachs and Morgan Stanley as underwriters in CStone Pharmaceuticals' US$285 million IPO and listing on the HKEX
• Proposed Hong Kong IPO of Biokin Pharma and Shulan Health
• CooTek in its US$57 million IPO and listing on the NYSE
• VCredit in its US$163 million IPO and listing on the HKEX
• OneSmart in its US$179 million IPO and listing on the NYSE
• Underwriters in Four Season Education's US$101 million IPO and listing on the NYSE
• Secoo in its US$111 million IPO and listing on the NYSE

M&A and Private Equity

• Asymchem in its acquisition of the API Pilot Plant and R&D Laboratory at the former Pfizer UK Sandwich Site, which marks the establishment of Asymchem's first Europe-based R&D and manufacturing hub 
• Lupeng Pharmaceutical in its US$35 million Series Pre-B financing
• Pulnovo Medical in its latest financing round totaling tens of millions of dollars
• Asymchem in its agreement to acquire Snapdragon Chemistry, a US-based chemical technology company
• JD.com and JD Finance in the US$500 million joint ventures for e-commerce and fintech services in Thailand with Central Group, the largest retail conglomerate in Thailand, and Provident Capital
• Ctrip.com in its acquisition of a minority shareholding in mobike Ltd
• Ctrip.com in its acquisition of a minority shareholding in a leading internet company
• Ocean Link, a private equity fund, in its acquisition of a minority shareholding in Ma Feng Wo
• Baidu Inc. in its sales and spin-off of Baidu Waimai
• Unilever in its acquisition of a majority shareholding in a leading Chinese water purifier business
• Alibaba in its acquisition of a minority shareholding in China Business News
• Sequoia Capital (China) in its acquisition of minority shareholdings in various internet companies
• Yunfeng Capital in its acquisition of a minority shareholding in an internet company
• E-House in its acquisition of a minority shareholding in a wealth management company